Daily Management & Dietary Therapy
At a Glance
Managing LCHAD deficiency requires a strict low-fat, high-carbohydrate diet to prevent toxic fat buildup. Alternative fuels like MCT oil or Triheptanoin (Dojolvi) provide essential energy, while strict maximum fasting times and cornstarch are used to maintain safe blood sugar levels overnight.
Managing LCHAD deficiency on a daily basis is a commitment to precision and consistency. Because your child’s body cannot process the long-chain fats found in most foods, your primary goal is to provide alternative fuels and ensure the body never enters a state of “starvation” (fasting) that would trigger fat burning [1][2].
The Foundation: A Low-Fat, High-Carbohydrate Diet
The cornerstone of life with LCHAD is a diet that is strictly low in long-chain fats and high in carbohydrates.
- Restriction: Long-chain fats (found in most oils, meats, and dairy) must be limited because the body cannot break them down, leading to the toxic buildup described in earlier pages [1].
- Energy Supply: Carbohydrates (sugars and starches) provide the quick energy your child’s body needs. Many families use uncooked cornstarch (mixed in liquid) to provide a slow-release source of sugar, especially overnight, to help keep blood sugar stable [3].
While long-chain fats are restricted, your child still needs age-appropriate lean protein for growth, as well as Essential Fatty Acids (EFAs) [1]. EFAs (like linoleic acid) are long-chain fats the body must have to prevent skin lesions, stunted growth, and neurological issues. Your metabolic dietitian will prescribe exact amounts of specific oils (like walnut or flaxseed) to safely meet this need without causing toxic buildup [4].
Day-to-day, this means safe foods primarily include fruits, vegetables, grains, and very lean proteins. You will need to learn how to expertly read nutrition labels to check for Long-Chain Triglycerides (LCTs) (often listed simply as “Fat” or “Total Fat” on the label) [1].
Alternative Fuel Sources: MCT and Triheptanoin
Since your child can’t use most long-chain fats, doctors provide “shortcut” fats that the body can use. These bypass the LCHAD enzyme “blockage” to provide energy directly to the cells.
1. Medium-Chain Triglyceride (MCT) Oil
MCT oil is a standard supplement for LCHAD deficiency [5]. Because MCTs are shorter than long-chain fats, the body can process them without needing the LCHAD enzyme. This provides a vital energy source for the heart and muscles [6].
2. Triheptanoin (Dojolvi)
Triheptanoin is a newer, FDA-approved medication (also known as an anaplerotic agent) [7]. While MCT oil has 8 or 10 carbons, Triheptanoin has 7 carbons.
- Replenishing the Engine: When Triheptanoin breaks down, it creates specific molecules that “refill” the Citric Acid Cycle (the body’s main energy-producing engine) [8][9].
- Benefits: Studies have shown that some patients on Triheptanoin experience fewer hospitalizations and better muscle stability compared to those on traditional MCT oil [10][11].
The Rule of Fasting: Maximum Intervals
In LCHAD deficiency, fasting is the enemy. You must follow strict maximum fasting times that change as your child grows [3].
- Infants: Often need to eat every 2 to 4 hours, including throughout the night [5].
- Toddlers and Children: As they grow, they may be able to go 6 to 8 hours (with the help of cornstarch), but these limits must always be set by your metabolic specialist [12].
- Nighttime: If a child cannot safely sleep through the night without their blood sugar dropping, a gastric tube (G-tube) may be used to provide continuous feeding while they sleep [5].
The L-Carnitine Controversy
L-carnitine is a supplement often used in metabolic disorders to help move fats into the mitochondria and clear out toxins. However, its use in LCHAD deficiency is highly nuanced:
- The Benefit: It can help prevent a carnitine deficiency and may help reduce oxidative stress [13][14].
- The Risk: Medically, L-carnitine binds to the stalled long-chain fats, converting them into long-chain acylcarnitines. If given in high doses, these specific compounds can build up and are highly arrhythmogenic (meaning they can cause dangerous disruptions to the heart’s rhythm) [15].
- Action Step: Always ask your specialist explicitly about their stance on L-carnitine for your child before starting any supplements to ensure you are safely navigating this balance [13].
Daily management is a balancing act of providing enough fuel to keep the “engine” running while avoiding the specific fats that the engine can’t handle. Your diligence in these daily routines is what prevents crises and protects your child’s long-term health [1]. You do not have to do this alone. Connecting with groups like the Fatty Oxidation Disorders (FOD) Family Support Group can provide immense practical advice and emotional support from parents who understand exactly what you are going through.
Common questions in this guide
What foods should my child avoid with LCHAD deficiency?
How long can a child with LCHAD go without eating?
What is the difference between MCT oil and Triheptanoin (Dojolvi)?
Why might L-carnitine be dangerous for a child with LCHAD deficiency?
How can I keep my child's blood sugar stable overnight?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the specific 'maximum fasting time' for my child at their current age?
- 2.Given the debate over L-carnitine, what dose is my child on and how are we monitoring for potential long-chain acylcarnitine buildup?
- 3.Is my child a candidate for Triheptanoin (Dojolvi), and how does it compare to their current MCT oil regimen?
- 4.What percentage of my child's total calories should come from fat versus carbohydrates?
- 5.How can we safely incorporate cornstarch into my child's diet to extend their fasting window overnight?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Ophthalmic Symptoms of Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Report of Three Cases.
Lange N, Bodetko AM, Mozrzymas R, Kowal-Lange A
Case reports in ophthalmology 2024; (15(1)):310-319 doi:10.1159/000537895.
PMID: 38595698 - 2
Regulatory news: Dojolvi (triheptanoin) as a source of calories and fatty acids in long-chain fatty acid oxidation disorders: FDA approval summary.
Zand D, Doan J, Yi S, et al.
Journal of inherited metabolic disease 2021; (44(3)):515-517 doi:10.1002/jimd.12377.
PMID: 33729583 - 3
Nutritional Management of Patients with Fatty Acid Oxidation Disorders.
Peña-Quintana L, Correcher-Medina P
Nutrients 2024; (16(16)) doi:10.3390/nu16162707.
PMID: 39203843 - 4
Evidence that Oxidative Disbalance and Mitochondrial Dysfunction are Involved in the Pathophysiology of Fatty Acid Oxidation Disorders.
Ribas GS, Vargas CR
Cellular and molecular neurobiology 2022; (42(3)):521-532 doi:10.1007/s10571-020-00955-7.
PMID: 32876899 - 5
Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System.
El-Gharbawy A, Vockley J
Pediatric clinics of North America 2018; (65(2)):317-335 doi:10.1016/j.pcl.2017.11.006.
PMID: 29502916 - 6
Lipidomic and Proteomic Alterations Induced by Even and Odd Medium-Chain Fatty Acids on Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders.
Alatibi KI, Tholen S, Wehbe Z, et al.
International journal of molecular sciences 2021; (22(19)) doi:10.3390/ijms221910556.
PMID: 34638902 - 7
Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases.
Wehbe Z, Tucci S
Journal of inherited metabolic disease 2020; (43(3)):385-391 doi:10.1002/jimd.12199.
PMID: 31778232 - 8
Anaplerotic Therapy Using Triheptanoin in Two Brothers Suffering from Aconitase 2 Deficiency.
Penkl M, Mayr JA, Feichtinger RG, et al.
Metabolites 2024; (14(4)) doi:10.3390/metabo14040238.
PMID: 38668366 - 9
Ketogenic and anaplerotic dietary modifications ameliorate seizure activity in Drosophila models of mitochondrial encephalomyopathy and glycolytic enzymopathy.
Fogle KJ, Smith AR, Satterfield SL, et al.
Molecular genetics and metabolism 2019; (126(4)):439-447 doi:10.1016/j.ymgme.2019.01.008.
PMID: 30683556 - 10
Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
Yang E, Kruger E, Yin D, et al.
Molecular genetics and metabolism 2024; (142(1)):108350 doi:10.1016/j.ymgme.2024.108350.
PMID: 38458123 - 11
The effect of triheptanoin treatment on clinical and laboratory outcomes in patients with long-chain fatty acid oxidation disorder.
Köse E, İnci A, Yazıcı H, et al.
European journal of pediatrics 2025; (184(6)):382 doi:10.1007/s00431-025-06216-3.
PMID: 40448841 - 12
Clinical manifestations and management of fatty acid oxidation disorders.
Merritt JL, MacLeod E, Jurecka A, Hainline B
Reviews in endocrine & metabolic disorders 2020; (21(4)):479-493 doi:10.1007/s11154-020-09568-3.
PMID: 32654032 - 13
Diagnosis, Treatment, and Clinical Outcome of Patients with Mitochondrial Trifunctional Protein/Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency.
De Biase I, Viau KS, Liu A, et al.
JIMD reports 2017; (31()):63-71 doi:10.1007/8904_2016_558.
PMID: 27117294 - 14
Oxidative damage in mitochondrial fatty acids oxidation disorders patients and the in vitro effect of l-carnitine on DNA damage induced by the accumulated metabolites.
de Moraes MS, Guerreiro G, Sitta A, et al.
Archives of biochemistry and biophysics 2020; (679()):108206 doi:10.1016/j.abb.2019.108206.
PMID: 31760122 - 15
Two siblings with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency suffered from rhabdomyolysis after l-carnitine supplementation.
Watanabe K, Yamada K, Sameshima K, Yamaguchi S
Molecular genetics and metabolism reports 2018; (15()):121-123 doi:10.1016/j.ymgmr.2018.03.007.
PMID: 30023301
This page provides educational information about dietary management for LCHAD deficiency. Always consult your pediatric metabolic specialist and registered dietitian before making any changes to your child's diet, fasting intervals, or supplements.
Get notified when new evidence is published on Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.